Tutti gli studi
Attivo ma non reclutanteFASE1, FASE2INTERVENTISTICO

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

This research is looking at a new medicine called acalabrutinib (also known as ACP-196) for adults with specific blood cancers such as chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Richter's Syndrome, or prolymphocytic leukaemia. The main goal is to find out if this medicine is safe and how well it works, especially for people whose cancer has come back or hasn't responded to at least two previous treatments. Acalabrutinib is a type of drug that targets a specific protein in cancer cells called BTK, aiming to stop the cancer from growing. This study is in its early stages (Phase 1 and 2), which means it's one of the first times it's being tested in a larger group of patients.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE1, FASE2
Sponsor
Acerta Pharma BV
Obiettivo di iscrizione
306
Inizio
30 Jan 2014
Completamento stimato
09 Jun 2027

Risultati

Risultati di questo studio

Pubblicato September 2022

I risultati di questo studio sono stati pubblicati.

Risultato principale
Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1
Participants with DLTs in Phase 1 are reported. The DLT was defined as any of the following events unless the adverse event is clearly related to disease progression or the participant's current medical history and associated comorbidities: (1) Any Grade 3 or greater nonhematologic toxicity with the exceptions of alopecia and Grade 3 nausea, vomiting, and diarrhea that respond to supportive therapy; (2) Hematologic toxicities including Grade 4 neutropenia lasting more than 5 days, Grade 4 or Grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion, Grade 3 or greater febrile neutropenia (body temperature of 38.5 degrees Celsius or more), or Grade 4 anemia, unexplained by underlying disease; or (3) Dosing delay due to toxicity for \> 7 consecutive days.
Risultati completi nel registro

Di cosa tratta questo studio?

This study is investigating a new treatment called acalabrutinib, which is designed for adults living with certain types of blood cancer. These include chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Richter's Syndrome, and prolymphocytic leukaemia. These conditions affect your white blood cells, which are important for fighting infections. Sometimes, these conditions can be challenging to treat, especially if they return after initial treatments or don't respond to them.

The main aim of this research is to see if acalabrutinib is a safe and effective option for patients in these situations. Acalabrutinib works by targeting a specific pathway within the cancer cells, which helps to stop them from growing and spreading. By understanding its safety and how well it helps control the cancer, doctors can learn if it could become a valuable new treatment option in the future. This is a crucial step in developing better ways to help people with these blood cancers.

Taking part in a study like this helps medical science advance. Every new treatment that becomes available has gone through similar research. By participating, you could be helping not only yourself but also many others in the future who are facing similar health challenges. It's about finding new and better ways to fight these illnesses.

Punti chiave

  • This study is testing a promising new medicine for specific blood cancers.
  • It's for people whose cancer hasn't responded to other treatments, or has returned.
  • Participation involves taking a new medicine and having regular health checks.
  • The main goals are to check the medicine's safety and how well it works.
  • You can stop taking part at any time without affecting your normal care.

Chi può essere idoneo?

This study is looking for adults aged 18 or over who have been diagnosed with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Richter's Syndrome, or prolymphocytic leukaemia. Importantly, your cancer must have either returned after at least two previous treatments, or not responded well to those treatments.

To be considered for this study, your cancer needs to be active and measurable. This means doctors need to be able to see signs of the disease, such as lymph nodes that are at least 2cm in size. Your active disease should also be causing symptoms that typically require treatment, such as anaemia (low red blood cells), a very enlarged spleen or lymph nodes, or if your white blood cell count is rapidly increasing. Other reasons could include serious symptoms like unexplained weight loss, persistent fevers, or night sweats.

There are also other detailed medical checks to make sure the study medicine is safe for you. Your blood test results, general health, and other medical conditions will be carefully reviewed by the study doctors to see if this study is a good fit for you. Not everyone with these conditions will be able to join, as the study needs to ensure it's safe to take part.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Do you have a confirmed diagnosis of CLL, SLL, Richter's Syndrome, or Prolymphocytic Leukaemia?
  3. Has your cancer come back or not responded to at least two previous treatments?
  4. Do you have active cancer, such as enlarged lymph nodes measuring at least 2cm?
  5. Are you experiencing symptoms that usually require treatment, like significant tiredness, fevers, or rapidly increasing white blood cells?
  6. Are you able to attend regular follow-up appointments and tests?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you will be given the new medicine, acalabrutinib. The study team will regularly check your health, blood tests, and how you are responding to the treatment. This will involve regular visits to the clinic, where you will have examinations and probably several blood tests. They will also measure your lymph nodes and check for any changes in your symptoms. The frequency of visits and tests will be explained in detail by the study team, but they are generally more frequent at the start of the study. You will be closely monitored for any side effects or changes in your condition. The total duration of your participation in the study will depend on how you respond to the treatment and the study plan, but this will be clearly communicated to you.

Rischi e benefici potenziali

Participating in this study might offer some potential benefits. You would be among the first to receive this new treatment for your condition, which could potentially help control your cancer if other options haven't worked. However, there are also potential risks involved. All medicines can have side effects, and since this is a new drug, not all potential side effects are fully known. The study team will carefully monitor you for any side effects and will explain what is currently known about them. Your health and safety are their top priority. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (12)

  • Sito di Ricerca
    Codice postale verificato
    Boston, Stati Uniti
  • Sito di Ricerca
    Codice postale verificato
    New Hyde Park, United States
  • Sito di Ricerca
    Codice postale verificato
    New York, Stati Uniti
  • Sito di Ricerca
    Codice postale verificato
    Columbus, Stati Uniti
  • Sito di Ricerca
    Codice postale verificato
    Fort Worth, United States
  • Sito di Ricerca
    Codice postale verificato
    Salt Lake City, United States
  • Sito di Ricerca
    Codice postale verificato
    Seattle, Stati Uniti
  • Sito di Ricerca
    Codice postale verificato
    Tacoma, United States
  • Sito di Ricerca
    Codice postale verificato
    Milano, Italia
  • Sito di Ricerca
    Codice postale verificato
    Leeds, Regno Unito
  • Sito di Ricerca
    Codice postale verificato
    Londra, Regno Unito
  • Sito di Ricerca
    Codice postale verificato
    Oxford, Regno Unito

Domande comuni

What is acalabrutinib?

Acalabrutinib is a new medicine being tested. It works by targeting a specific protein in cancer cells to help stop them from growing.

Per quali tipi di cancro è questo studio?

This study is for adults with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Richter's Syndrome, or prolymphocytic leukaemia.

Chi può partecipare a questo studio?

You need to be over 18, and your cancer must have come back or not responded to at least two previous treatments. Other specific medical requirements also apply.

What will happen if I join the study?

You'll take the study medicine and have regular check-ups, blood tests, and other assessments to monitor your health and how the treatment is working.

Posso lasciare lo studio in qualsiasi momento?

Yes, you have the right to stop participating in the study at any point, and this will not affect your ongoing medical care.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.